EUVIMEDEUVIMED entdecken
Open Access · CC BY 4.0

Rapid development and deployment of high‐volume vaccines for pandemic response

Zoltán Kis iD, Cleo Kontoravdi, Antu K Dey, Robin Shattock, Nilay Shah

Journal of Advanced Manufacturing and Processing · 2020-07 · 2 (3)

DOI: 10.1002/amp2.10060 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Journal of Advanced Manufacturing and Processing, online erschienen am 29.06.2020. Verfasst von Zoltán Kis und 4 weiteren Autor:innen. Beteiligte Einrichtung: Centre for Process Systems Engineering, Department of Chemical Engineering, Faculty of Engineering Imperial College London London UK. Die Arbeit wurde bisher 99-mal zitiert (Crossref) und nennt 61 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Engineering and Physical Sciences Research Council.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Overcoming pandemics, such as the current Covid‐19 outbreak, requires the manufacture of several billion doses of vaccines within months. This is an extremely challenging task given the constraints in small‐scale manufacturing for clinical trials, clinical testing timelines involving multiple phases and large‐scale drug substance and drug product manufacturing. To tackle these challenges, regulatory processes are fast‐tracked, and rapid‐response manufacturing platform technologies are used. Here, we evaluate the current progress, challenges ahead and potential solutions for providing vaccines for pandemic response at an unprecedented scale and rate. Emerging rapid‐response vaccine platform technologies, especially RNA platforms, offer a high productivity estimated at over 1 billion doses per year with a small manufacturing footprint and low capital cost facilities. The self‐amplifying RNA (saRNA) drug product cost is estimated at below 1 USD/dose. These manufacturing processes and facilities can be decentralized to facilitate production, distribution, but also raw material supply. The RNA platform technology can be complemented by an a priori Quality by Design analysis aided by computational modeling in order to assure product quality and further speed up the regulatory approval processes when these platforms are used for epidemic or pandemic response in the future.

Schlagwörter

Stichwörter der Autor:innen

Quality by DesignRNA vaccinesbioprocess modelingdistributed manufacturingpandemic‐response vaccine manufacturingtechno‐economic modelingvaccine platform technology

Autor:innen und Institutionen

  • Centre for Process Systems Engineering, Department of Chemical Engineering, Faculty of Engineering Imperial College London London UK.
  • International AIDS Vaccine Initiative (IAVI) New York New York USA.
  • Department of Infectious Disease, Faculty of Medicine Imperial College London UK.

ORCID-Profile: Zoltán Kis

Förderung

  • Engineering and Physical Sciences Research Council

Zitieren

APA

Kis, Z., Kontoravdi, C., Dey, A. K., Shattock, R., & Shah, N. (2020). Rapid development and deployment of high‐volume vaccines for pandemic response. Journal of Advanced Manufacturing and Processing, 2(3). https://doi.org/10.1002/amp2.10060

Vancouver

Kis Z, Kontoravdi C, Dey AK, Shattock R, Shah N. Rapid development and deployment of high‐volume vaccines for pandemic response. Journal of Advanced Manufacturing and Processing. 2020;2(3). doi:10.1002/amp2.10060

BibTeX
@article{Kis2020,
  author = {Kis, Zoltán and Kontoravdi, Cleo and Dey, Antu K and Shattock, Robin and Shah, Nilay},
  title = {Rapid development and deployment of high‐volume vaccines for pandemic response},
  journal = {Journal of Advanced Manufacturing and Processing},
  year = {2020},
  volume = {2},
  number = {3},
  doi = {10.1002/amp2.10060}
}
Kostenlos starten →